CXCR7:一个与肿瘤发生有关的趋化因子SDF-1和I-TAC的新受体

来源 :中国肿瘤生物治疗杂志 | 被引量 : 0次 | 上传用户:qijisama
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
研究表明SDF-1(CXCL12)能调控许多重要的生物过程,包括心脏与神经的发育、干细胞运动、血管形成、凋亡及肿瘤发生。历来认为,SDF-1是通过CXCR4这个唯一的受体来调控这些不同的过程。本研究发现了SDF-1的一个新受体,称为CX-CR7。CXCR7除了能与SDF-1高亲和力结合外,还能结合另外 Studies have shown that SDF-1 (CXCL12) regulates many important biological processes, including heart and nerve development, stem cell motility, angiogenesis, apoptosis and tumorigenesis. Historically, SDF-1 regulates these diverse processes through the sole receptor for CXCR4. This study found a new receptor for SDF-1, called CX-CR7. CXCR7 binds to SDF-1 in addition to its high affinity
其他文献
期刊
“十五”后期,浙江省将面临严重缺电局面,今后5年将建设10 GW的发电工程.利用原有老的发电基地建设新的电厂,即所谓“一厂两站”方案,不仅解决厂址资源紧缺的矛盾,且具有建设
期刊
重症监护病房(ICU)是危重症患者病情监测和治疗的单位,也是医院易感人群和感染因素集中的场所,其感染发生的概率比其他科室高,而ICU医院感染问题是导致抢救最终失败的重要原
期刊
Holder[1] 等 ( 1965 )报道了低剂量全身照射对多发性骨髓瘤患者的临床疗效。Johnson[2 ] 等 ( 1967)首次将低剂量全身照射用于治疗非何杰金氏淋巴瘤 ,并肯定了其抗肿瘤效果。当时由于受理
期刊
Objective: To study the therapeutic effect of Compound Biejia Ruangan prescription (CBRP) on rat model with pulmonary fibrosis induced by bleomycin. Methods: Fi
Severeacuterespiratorysyndrome(SARS)isanewacuteinfectiousdiseasewhich quicklyspreadsanddevelops,resultinginhighmortality.Sincetherelacksanydiagnosticmethodwithh
At present, quality of life (QOL) has become a relevant measure of efficacy in clinical trials. Its use is spreading, and its importance is growing as a valid
期刊